SparingVision Eyes The Clinic With Two Assets After €75m Series B Raise
Funded Until Second Half Of 2025
Executive Summary
The French firm will use the funds to establish proof-of-concept for two gene therapy programs in a rare eye condition as it strives to become a world leader in ophthalmic genomic medicine, its CEO tells Scrip.